Merck's Bacterial-Infection Drug Recarbrio Approved by FDA
17 Juillet 2019 - 01:45PM
Dow Jones News
By Dave Sebastian
Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug
Administration has approved its Recarbrio drug injection for
urinary-tract and intra-abdominal bacterial infections.
The New Jersey pharmaceutical company said it anticipates to
make Recarbrio available later this year.
The drug is a combination of imipenem and cilastatin--both
antibacterial components--as well as relebactam, which protects
imipenem from certain enzymes, Merck said.
Relebactam received the FDA's Qualified Infectious Disease
Product designation for the treatment of complicated urinary tract
and complicated intra-abdominal bacterial infections, and the FDA
gave Recarbrio's drug application a priority-review designation,
the company said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
July 17, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024